<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles H Hennekens, MD, FACPM, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jose Lopez-Sendon, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joann G Elmore, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with established cardiovascular disease (CVD) have a high risk of subsequent CVD events, including myocardial infarction (MI), stroke, and death. Many individuals without established CVD are also at very high risk, such as those with metabolic syndrome, multiple risk factors, diabetes, or chronic kidney disease.</p><p>For all these high-risk patients, therapeutic lifestyle changes, which include increased physical activity, dietary modification/weight loss, and smoking cessation are of proven benefit and improve outcomes beginning within a matter of weeks. In addition, adjunctive drug therapies of proven benefit include statins and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, whose benefits are at least additive.</p><p>This topic is a broad overview of our approach to the prevention of CVD events in those with established CVD or at very high risk. Our approach in those without CVD is presented separately. (See  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>For the purpose of this topic, we are addressing the broad group of patients who have signs or symptoms of established CVD such as angina, transient ischemic attack, or claudication or those who have had a discrete adverse CVD event such as MI or stroke. In addition, this topic is meant to include recommendations for those at high risk but without overt CVD. High risk is defined directly below. (See <a class="local">'Identifying patients at high risk'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">IDENTIFYING PATIENTS AT HIGH RISK</span><span class="headingEndMark"> — </span>Among patients without established disease, very high-risk individuals are defined in most guidelines as those whose 10-year risk is &gt;20 percent, and high-risk individuals are defined as those whose 10-year risk is &gt;7.5 to 20 percent according to cardiovascular disease (CVD) risk factor tables or scores [<a href="#rid1">1-3</a>] (see  <a class="medical medical_review" href="/d/html/114029.html" rel="external">"Cardiovascular disease risk assessment for primary prevention: Risk calculators"</a>). These higher-risk subjects are likely to include most patients with diabetes or chronic kidney disease with estimated glomerular filtration rate &lt;60 mL/min/1.73 m<sup>2</sup>, as well as many with metabolic syndrome (the constellation of overweight and obesity, dyslipidemia, hypertension, and insulin resistance), a precursor of diabetes. (See  <a class="medical medical_review" href="/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a> and  <a class="medical medical_review" href="/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)", section on 'Epidemiology and risk factors'</a> and  <a class="medical medical_review" href="/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease", section on 'Chronic kidney disease as an independent risk factor for CHD'</a> and  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Reducing the risk of macrovascular disease'</a>.)</p><p>In addition, some guidelines define individuals to be at high risk if an imaging study documents atherosclerosis in the arterial circulation.</p><p class="headingAnchor" id="H9044882"><span class="h2">Older adults</span><span class="headingEndMark"> — </span>Age is a major risk factor for all clinical manifestations of CVD. As the relative benefits of both therapeutic lifestyle changes and adjunctive drug therapies appear to be similar across all ages up to about 85 years, the absolute benefits are larger in older adults. We offer preventive strategies to older adults with the caveat that randomized trials have enrolled and followed patients into their 80s, but there are far more patients in middle than older ages.</p><p>In addition, for many older adults, maintaining a high quality of life may be more important than quantity of life. These issues need to be considered by the health care provider and each of their older adult patients.</p><p>Since older adults tend to be on many drug therapies, clinicians should be aware of the greater potential for drug-drug interactions, especially in those with high-risk comorbidities such as chronic kidney disease.</p><p class="headingAnchor" id="H9"><span class="h1">DYSLIPIDEMIA</span><span class="headingEndMark"> — </span>Management of dyslipidemia, particularly reduction of LCL cholesterol, is essential in individuals with or at very high risk of cardiovascular disease. We treat these patients with evidence-based doses of a statin or other pharmacotherapy. Management and treatment goals are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">HYPERTENSION</span><span class="headingEndMark"> — </span>Our recommendations for the establishment of goal blood pressure and the use of drug therapies are discussed separately. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a> and  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>We recommend lifestyle changes for all apparently healthy individuals. In addition, this recommendation should be especially emphasized to patients with blood pressures of 120/80 mmHg or greater [<a href="#rid4">4-6</a>]. Therapeutic lifestyle changes of proven benefit include weight loss, increased physical activity, dietary sodium restriction, and reduction or avoidance of alcohol. Institution of these therapeutic lifestyle changes pose little or no risks, and all are likely to beneficial for all patients regardless of blood pressure. (See  <a class="medical medical_review" href="/d/html/3878.html" rel="external">"Diet in the treatment and prevention of hypertension"</a> and  <a class="medical medical_review" href="/d/html/3875.html" rel="external">"Overweight, obesity, and weight reduction in hypertension"</a> and <a class="local">'Lifestyle modifications'</a> below.)</p><p class="headingAnchor" id="H3965524645"><span class="h1">DIABETES MELLITUS</span><span class="headingEndMark"> — </span>The benefits of glycemic control on microvascular as well as macrovascular disease in patients with type 1 and type 2 diabetes are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus", section on 'Macrovascular disease'</a> and  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">LIFESTYLE MODIFICATIONS</span><span class="headingEndMark"> — </span>Lifestyle modifications such as smoking cessation, increase in physical activity, and improvement in diet have important beneficial effects on CVD morbidity and mortality that begin relatively shortly after their institution [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H1912428801"><span class="h2">Diet</span><span class="headingEndMark"> — </span>In observational studies, individuals who self-select for healthy diets experience significantly lower CVD event rates. Dietary interventions, in particular a Mediterranean diet, improve outcomes in patients with established CVD [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/5364.html" rel="external">"Healthy diet in adults"</a>.)</p><p>We agree with the following dietary recommendations of the 2019 American College of Cardiology/American Heart Association (ACC/AHA) guideline on primary prevention of CVD [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>We encourage adherence to diets that emphasize high intakes of vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diets should minimize the intake of <strong>trans</strong> fats, red meat and processed red meats, refined carbohydrates, and sweetened beverages. (See <a class="local">'Dyslipidemia'</a> above.)</p><p></p><p>The European Society of Cardiology (ESC) guidelines on CVD prevention (both primary and secondary) make a recommendation for a Mediterranean or similar diet to reduce CVD risk [<a href="#rid11">11</a>]. Further, they suggest replacing saturated with unsaturated fats, reducing salt intake, choosing a plant-based food pattern high in fiber, and eating fish, preferably fatty, at least once a week. (See  <a class="medical medical_review" href="/d/html/5364.html" rel="external">"Healthy diet in adults", section on 'Mediterranean diet'</a> and  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>For patients with known CVD or those at high risk who consume fish or are willing to do so, we recommend that they consume at least one to two servings per week of oily fish, which is consistent with the AHA recommendations [<a href="#rid12">12</a>]. Consumption of fish as part of a healthy diet is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5364.html" rel="external">"Healthy diet in adults", section on 'Protein-rich foods'</a>.)</p><p class="headingAnchor" id="H3981254720"><span class="h2">Weight reduction</span><span class="headingEndMark"> — </span>In large-scale prospective studies [<a href="#rid13">13</a>], individuals who are overweight or obese have increased risks for CVD across a large range of levels. In the United States as well as other resource-rich countries, overweight and obesity may be overtaking smoking as the leading avoidable cause of premature death [<a href="#rid14">14</a>]. Weight reduction is difficult to achieve and maintain; among the 90 percent of subjects who are successful initially, about 90 percent of those eventually regain the lost weight. However, a clear benefit of weight reduction on cardiovascular outcomes has not been clearly demonstrated. (See  <a class="medical medical_review" href="/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a> and  <a class="medical medical_review" href="/d/html/1529.html" rel="external">"Obesity: Association with cardiovascular disease"</a>.)</p><p>Overweight and obesity also are major contributors to metabolic syndrome a constellation of hypertension, dyslipidemia, and insulin resistance leading to diabetes. In the United States, metabolic syndrome, which confers high risk of a first CVD event, occurs in about 40 percent of individuals over age 40. In addition, overweight and obesity in the absence of metabolic syndrome also confer significantly increased risks of CVD [<a href="#rid15">15-20</a>].</p><p>All patients with CVD should have a measurement of waist circumference and a calculation of body mass index (BMI; calculated as weight in kilograms divided by height in meters squared). Weight reduction is optimally achieved with multiple strategies, including diet, increased physical activity, and possible pharmacologic therapy. (See  <a class="medical medical_review" href="/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p>The 2018 US Preventive Services Task Force (USPSTF) recommendation statement on weight loss to prevent obesity-related morbidity and mortality in adults recommends that clinicians offer or refer adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3636580544"><span class="h2">Physical activity</span><span class="headingEndMark"> — </span>Regular physical activity has numerous cardiovascular benefits, including weight loss, improvements in lipid profile, and reductions in blood pressure, as well as prevention and management of type 2 diabetes. All these beneficial effects lead to improvements in CVD morbidity and mortality. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease"</a>.)</p><p>Prior to initiation of an activity program, most high-risk patients should undergo risk assessment with a physical activity history and/or an exercise test [<a href="#rid22">22</a>]. (See <a class="local">'Cardiac rehabilitation programs'</a> below.)</p><p>We agree that the following recommendation for physical activity made in the 2019 ACC/AHA guideline on primary prevention of CVD is applicable to secondary prevention: Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per week of vigorous-intensity physical activity [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2452880840"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>Smoking cessation produces statistically significant and clinically important benefits on CVD, beginning within a matter of months and reaching the nonsmoker in three to five years. These benefits have been shown in secondary and primary prevention. (See  <a class="medical medical_review" href="/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of observational studies, among 12,603 smokers who had a prior myocardial infarction (MI), coronary artery bypass graft surgery, angioplasty, or known coronary heart disease (CHD) [<a href="#rid23">23</a>], the relative risk (RR) of mortality for quitters compared with those who continued to smoke was 0.64 (95% CI 0.58-0.71).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort study of 2619 patients who survived to hospital discharge after a first MI [<a href="#rid24">24</a>], among those who quit smoking (patients who quit and restarted were considered active smokers), the RR for recurrent events progressively and significantly decreased with longer duration of cessation (RR 1.62 at 0 to &lt;6 months, 1.60 from 6 to &lt;18 months, 1.48 for 18 to &lt;36 months, and 1.02 for ≥36 months).</p><p></p><p>The various major effective modalities to attain and sustain smoking cessation are discussed separately. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>Passive smoking has been clearly linked with a higher risk of CVD [<a href="#rid25">25</a>]. Banning smoking in public places quickly reduced the incidence of acute MI in many observational studies [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1563669895"><span class="h2">Alcohol</span><span class="headingEndMark"> — </span>Moderate alcohol consumption is associated with a reduced risk of CHD; however, binge drinking increases the risk for CHD [<a href="#rid27">27-31</a>]. The effect of alcohol consumption on CVD is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption", section on 'Effect of alcohol on cardiovascular risk'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Cardiac rehabilitation programs</span><span class="headingEndMark"> — </span>We recommend referral to a comprehensive, outpatient cardiovascular rehabilitation program for all eligible patients with a recent acute coronary syndrome (ACS) or revascularization procedure [<a href="#rid22">22</a>]. Other patients, such as those with these diagnoses in the past year, those with chronic angina, or those with peripheral artery disease, may be candidates for referral. These programs are usually designed to provide the patient with assistance in lifestyle modification. (See  <a class="medical medical_review" href="/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease", section on 'Comprehensive risk factor intervention'</a>.)</p><p class="headingAnchor" id="H17424083"><span class="h3">Text messaging</span><span class="headingEndMark"> — </span>Not all patients are able to attend a cardiac rehabilitation program, and many programs limit the number of sessions. Another way to deliver assistance to patients in the adoption of a healthy lifestyle may be for the patient to receive mobile phone text messages periodically. The TEXT ME study randomly assigned 710 patients with CHD to a text message-based prevention program that delivered semi-personalized text messages four times per week with advice, motivation, and information to improve diet, increase physical activity, and encourage smoking cessation (if applicable) [<a href="#rid32">32</a>]. At six months, the intervention group had statistically significant improvements in LDL cholesterol (79 versus 84 mg/dL), systolic blood pressure (128.2 versus 135.8 mmHg, BMI 29.0 versus 30.3), physical activity (936 versus 642.7 metabolic equivalent minutes/week), and percent of patients who smoked (26.0 versus 42.9).</p><p class="headingAnchor" id="H35"><span class="h1">ADJUNCTIVE THERAPIES</span><span class="headingEndMark"> — </span>All patients with established cardiovascular disease (CVD) and many other high-risk patients should receive <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and statin therapy. Other medications that may be of benefit in some patients include beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone blockers, platelet P2Y<sub>12 </sub>receptor blockers, <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, and oral anticoagulants. Administration of influenza vaccine also appears to be beneficial in patients with CVD.</p><p class="headingAnchor" id="H461246482"><span class="h2">Antiplatelet therapy</span><span class="headingEndMark"> — </span>For patients with established CVD, we recommend long-term <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy. Long-term antiplatelet therapy with aspirin reduces the risk of subsequent myocardial infarction (MI), stroke, and cardiovascular death among patients with a wide range of manifestations of occlusive CVD. In patients who are unable to take aspirin and in those with a history of gastrointestinal bleeding, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> is a reasonable alternative.</p><p>For patients who have undergone percutaneous coronary intervention (PCI) with stenting or those who have had an acute coronary syndrome (ACS), a P2Y<sub>12</sub> receptor blocker is added to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for some period of time.</p><p>The role of antiplatelet therapy in patients with CVD is discussed in numerous other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>In atherosclerotic CVD (see  <a class="medical medical_review" href="/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have undergone coronary artery stent placement (see  <a class="medical medical_review" href="/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>In the first year following ACS (see  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have had a stroke (see  <a class="medical medical_review" href="/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a>)</p><p></p><p>The use of dual antiplatelet therapy has been evaluated in populations other than those with ACS or those who have had PCI. In the THEMIS trial, 19,220 patients with chronic coronary syndrome and type 2 diabetes mellitus were randomly assigned to <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> 60 mg or placebo twice per day. All patients received low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> once per day. Patients assigned at random to ticagrelor and aspirin had a 10 percent lower risk of ischemic CVD events (cardiovascular death, MI, or stroke) at 40 months when compared with aspirin alone (7.7 versus 8.5 percent; hazard ratio [HR] 0.90, 95% CI 0.81-0.99) but a highly significant and clinically important large increases of major bleeding (2.2 versus 1.0 percent; HR 2.32, 95% CI 1.82-2.94) and intracranial hemorrhage (0.7 versus 0.5 percent; HR 1.71, 95% CI 1.18-2.48) [<a href="#rid33">33</a>]. Based on these data, the US Food and Drug Administration (FDA) approved dual antiplatelet therapy for this population with or without diabetes. As is the case for all such patients, the health care provider must weigh the benefits on occlusion against the risks on bleeding for each of their individual patients.</p><p>In a prespecified subgroup analysis of THEMIS (THEMIS-PCI) in the 11,154 patients with PCI, patients assigned to <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> had a 15 percent significant decreased incidence of ischemic CVD events compared with those assigned to aspirin and placebo (7.3 versus 8.6 percent; HR 0.85, 95% CI 0.74-0.97). In this subgroup, those assigned to ticagrelor and aspirin also had an over 80 percent significantly increased risks of major bleeding (2.0 versus 1.1 percent) [<a href="#rid34">34</a>]. Intracranial hemorrhage occurred in 0.6 percent of both groups. In the subgroup of patients with chronic coronary syndrome and type 2 diabetes mellitus with no history of PCI, there was no apparent benefit.</p><p>This subgroup analysis contributes to the formulation of the hypothesis that patients with stable coronary artery disease (CAD) and diabetes at very high ischemic risk and low bleeding risk may have a net benefit with long-term dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>. Health care providers may wish to consider these possibilities in discussions with their patients [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>.)</p><p>The role of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in patients without established CVD but at high risk is discussed separately. (See  <a class="medical medical_review" href="/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'All-cause mortality'</a>.)</p><p class="headingAnchor" id="H4059482214"><span class="h2">Anticoagulant therapy</span><span class="headingEndMark"> — </span>For most patients with stable CAD on antiplatelet therapy, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg orally twice per day and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> may be considered for some stable atherosclerotic CVD patients at high risk of cardiovascular events and low risk for bleeding, based on the COMPASS trial, which is presented below. Such patients include those with peripheral artery disease or a history of ischemic stroke, multivessel CAD, incomplete coronary revascularization, diabetes, patients with a body weight &gt;60 kg (132 pounds), prior coronary artery bypass surgery, chronic kidney disease, or multiple prior ischemic events. We do not recommend substituting or adding full-dose oral anticoagulant therapy to aspirin therapy in an attempt to lower the risk of subsequent CVD events.</p><p>The use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus anticoagulant therapy in patients with a specific indication for anticoagulant, such as atrial fibrillation or venous thromboembolic disease, is discussed separately. (See  <a class="medical medical_review" href="/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Our approach'</a> and  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p>In stable patients, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, an oral direct Xa inhibitor, has been tested in secondary CVD prevention using a very low-dose regimen added to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy.</p><p>In the COMPASS trial, 27,395 patients with stable CAD or peripheral arterial disease were randomly assigned to <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> plus <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, rivaroxaban alone, or aspirin alone with a mean follow-up of 23 months [<a href="#rid37">37</a>]. The dose of rivaroxaban in the combination arm was 2.5 mg orally twice per day; in the rivaroxaban-only arm, the dose was 5 mg orally twice per day. Compared with those assigned at random aspirin alone, patients assigned to rivaroxaban plus aspirin had a 22 percent significant decreases in cardiovascular mortality (1.7 versus 2.2 percent; HR 0.78, 95% CI 0.64-0.96) and 49 percent decrease in ischemic stroke (0.7 versus 1.4 percent; HR 0.51, 95% CI 0.38-0.68). There was also a possible but nonsignificant 14 percent reduction in MI (1.9 versus 2.2 percent; HR 0.86; 95% CI 0.70-1.05). As expected, those assigned to combination therapy had a 70 percent significant increase in major bleeding events (3.1 versus 1.9 percent; HR 1.70, 95% CI 1.40-2.05), with the gastrointestinal tract being the most common site of major bleeding. The risk of intracranial hemorrhage was comparable between the two groups. Mortality and cardiovascular outcomes were similar in the rivaroxaban-alone and aspirin-alone groups, but there were significantly more major bleeding events in those assigned to rivaroxaban and aspirin. Health care providers should be aware of the balance between prevention of thrombosis and causing serious bleeding.</p><p>The optimal antithrombotic strategy in patients with other reasons for anticoagulation, such as atrial fibrillation, is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'After 12 months'</a>.)</p><p>The role of anticoagulant therapy in secondary prevention in patients with an ACS is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a>.)</p><p class="headingAnchor" id="H2601362885"><span class="h2">Statins and other lipid-lowering agents</span><span class="headingEndMark"> — </span>The role of statin therapy in patients at high cardiovascular risk is discussed above. (See <a class="local">'Dyslipidemia'</a> above.)</p><p class="headingAnchor" id="H37"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>In patients with recent acute MI or in those with heart failure (HF) due to systolic dysfunction, oral beta blockers may be a part of their treatment regimen. The evidence supporting these recommendations is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p>In patients with chronic coronary syndrome and angina, beta blockers reduce the severity and frequency of anginal attacks. With the exception of patients with HF, the evidence is limited about whether beta blockers lower the risk of death in patients with chronic coronary syndrome when combined with contemporary secondary prevention strategies. Some of our contributors continue beta blockers indefinitely in patients with chronic coronary syndrome, while others stop them if they are not needed for control of symptomatic ischemia. (See  <a class="medical medical_review" href="/d/html/1466.html" rel="external">"Beta blockers in the management of chronic coronary syndrome", section on 'Efficacy of beta blockers in stable angina'</a> and  <a class="medical medical_review" href="/d/html/1466.html" rel="external">"Beta blockers in the management of chronic coronary syndrome", section on 'Survival'</a>.)</p><p class="headingAnchor" id="H38"><span class="h2">ACE inhibitors or ARBs</span><span class="headingEndMark"> — </span>Many patients with established CVD will benefit from ACE inhibitor or ARB therapy. The most common indications are attainment of goal blood pressure, the treatment of acute MI, or the presence of HF, left ventricular ejection fraction below 40 percent, diabetes, or proteinuric kidney disease. (See  <a class="medical medical_review" href="/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a> and  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p>Other high-risk individuals include those with diabetes or chronic kidney disease. In these high-risk patients, ACE inhibitors and ARBs have been hypothesized to have cardioprotective effects independent of blood pressure lowering, but the available evidence suggests that the attained blood pressure is of primary importance. ACE inhibitors or ARBs may also be a first-line drug of choice to control blood pressure in diabetic and metabolic syndrome patients with or without prior MI. (See  <a class="medical medical_review" href="/d/html/3815.html" rel="external">"Renin-angiotensin system inhibition in the treatment of hypertension", section on 'Specific indications for use'</a>.)</p><p class="headingAnchor" id="H1098288208"><span class="h2">Polypill</span><span class="headingEndMark"> — </span>Polypills combine fixed doses of medications such as <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, ace-inhibitor and statin into one pill and have been proposed as a method to increase medication adherence. Their use in primary prevention of CVD is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>In the Secondary Prevention of Cardiovascular Disease in the Elderly (SECURE) trial of nearly 2500 patients from 7 European countries with recent myocardial infarction (MI), treatment with a polypill containing <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (100 mg), <a class="drug drug_general" data-topicid="9851" href="/d/drug information/9851.html" rel="external">ramipril</a> (2.5, 5, or 10 mg), and <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> (20 or 40 mg) was shown to lower risk of major adverse cardiovascular events compared with usual care [<a href="#rid38">38</a>]. Eligible patients were either older than 75 or at least 65 years of age with at least one additional risk factor [diabetes mellitus, mild or moderate kidney disease, previous myocardial infarction (defined as infarction occurring before the index event), previous coronary revascularization]. The mean age of participants was 76 years and 70 percent were male. Time from MI to randomization was a median of 8 days (interquartile range 3 to 37).</p><p>After 36 months of follow-up, the following outcomes were observed:</p><p class="bulletIndent1"><span class="glyph">●</span>Those assigned to the polypill events had lower rates of cardiovascular events (cardiovascular death, nonfatal type 1 myocardial infarction, nonfatal ischemic stroke, or urgent revascularization): 9.5 versus 12.7 percent; hazard ratio [HR] 0.76, 95% CI 0.60-0.96) compared with the usual care group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There were no differences in blood pressure and LDL cholesterol levels during follow-up between the two treatment groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medication adherence as reported by the patients was higher in the polypill versus usual-care group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse event rates were similar between treatment groups.</p><p></p><p>The lack of difference in follow-up blood pressure or LDL cholesterol suggest that the <a class="drug drug_general" data-topicid="9851" href="/d/drug information/9851.html" rel="external">ramipril</a> and statin components of the polypill may have had pleiotropic effects, beyond the lowering of these risk factors, that resulted in lower rates of secondary CVD [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/4546.html" rel="external">"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"</a>.)</p><p class="headingAnchor" id="H5260668"><span class="h2">Mineralocorticoid receptor antagonist</span><span class="headingEndMark"> — </span>The use of a mineralocorticoid receptor antagonist (eg. <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> or epleronone) is recommended for certain patients with heart failure and reduced ejection fraction. This is described in detail elsewhere (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p class="headingAnchor" id="H987984841"><span class="h2">Colchicine</span><span class="headingEndMark"> — </span>For patients with chronic CAD who have been provided with recommendations for therapeutic lifestyle changes and prescribed appropriate preventive medications (which may include statins and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>), we suggest treatment with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> 0.5 (or 0.6) mg per day. In randomized trials in the secondary prevention of CAD, patients assigned to colchicine had improved outcomes. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Inflammation'</a>.)</p><p>The most common side effects (diarrhea, nausea, vomiting, and abdominal pain) are usually mild. Transient, and usually painless, elevations of creatinine kinase have also been reported; this may be related to other drugs such as statins or other lipid-lowering drugs [<a href="#rid40">40</a>]. The dosage of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> may need to be reduced in patients taking P-glycoprotein (P-gp) inhibitors or strong CYP3A4 inhibitors, including certain beta blockers, calcium channel blockers, or <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>. Colchicine is contraindicated in patients with renal or hepatic impairment.</p><p><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> reduced risks of CAD in the LoDoCo2 trial. This trial randomly assigned 5522 patients, 85 percent men, with chronic CAD to 0.5 mg of colchicine once per day or placebo [<a href="#rid41">41</a>]. After two and half years, those assigned to colchicine had a decreased risk of the primary composite endpoint (HR 0.69, 95% CI 0.57-0.83), with reductions in MI (3.0 versus 4.2 percent; HR 0.70, 95% CI 0.53-0.93) and ischemia-driven coronary artery revascularization (4.9 versus 6.4 percent; HR 0.75, 95% CI 0.60-0.94). The incidence of death from non-cardiovascular causes appeared higher in the colchicine group; however, this finding did not achieve statistical significance (0.7 versus 0.5 percent; HR 1.51, 95% CI 0.99-2.31). All-cause mortality was similar in both groups (RR 1.08, 95% CI 0.71-1.62). Colchicine produced no significant adverse effects except for a somewhat higher rate of myalgia (21.2 versus 18.5 percent). In post hoc subgroup analyses, benefits were similar among those with and without a history of prior ACS or timing of reported ACS [<a href="#rid42">42</a>]. A subsequent meta-analysis had similar findings to those of LoDoCo2 [<a href="#rid43">43</a>].</p><p>Prior studies have evaluated the use of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> in patients following ACS with similar results [<a href="#rid44">44,45</a>]. These are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Colchicine'</a>.)</p><p class="headingAnchor" id="H3439309578"><span class="h2">Sodium-glucose co-transporter 2 inhibitors</span><span class="headingEndMark"> — </span>Certain sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular outcomes in patients with heart failure with reduced ejection fraction (with or without diabetes mellitus) and in patients with type 2 diabetes mellitus and existing CVD. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Primary components of therapy'</a>.)</p><p class="headingAnchor" id="H789702654"><span class="h2">Marine omega-3 fatty acids</span><span class="headingEndMark"> — </span>Many patients with established CVD or at high risk of CVD have hypertriglyceridemia. The role of marine omega-3 fatty acid therapy in patients with hypertriglyceridemia is discussed separately. (See  <a class="medical medical_review" href="/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management", section on 'Marine omega-3 fatty acids'</a>.)</p><p>We do not routinely recommend marine omega-3 fatty acids in individuals with CAD without hypertriglyceridemia. For such patients, there is less evidence supporting their use. The OMEMI trial randomly assigned 1027 patients aged 70 to 82 years with a recent (within two to eight weeks) MI to treatment with 1.8 g marine n-3 polyunsaturated fatty acid or corn oil [<a href="#rid46">46</a>]. Among enrolled patients, the mean triglyceride level was 111 mg/dL, that is, most did not have hypertriglyceridemia (defined as a triglyceride level ≥150 mg/dL). The rate of the primary composite endpoint (nonfatal MI, unscheduled revascularization, stroke, all-cause death, or heart failure hospitalization) after two years was similar in both treatment groups (21.4 versus 20.0 percent; HR 1.08, 95% CI 0.82-1.42). The small sample size may have limited the ability to detect statistically significant differences in outcomes.</p><p class="headingAnchor" id="H43"><span class="h2">COVID-19 and influenza vaccination</span><span class="headingEndMark"> — </span>As with adults in the general population, we recommend annual influenza vaccine for patients with CVD [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p>We also encourage all patients with CVD to receive vaccination against COVID-19, due to increased risk of severity of COVID-19 infection  (<a class="graphic graphic_table graphicRef127477" href="/d/graphic/127477.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/127533.html" rel="external">"COVID-19: Myocardial infarction and other coronary artery disease issues"</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p>Individuals with established CVD and high-risk primary prevention subjects have increased risks for complications of influenza infection. In a cross-sectional study of 80,000 adults hospitalized with influenza (of whom 20 percent had chronic CVD, 20 percent chronic kidney disease, and 15 percent diabetes), 11.7 percent had an acute cardiovascular event during hospitalization, most commonly acute HF or acute ischemic heart disease [<a href="#rid47">47</a>].</p><p>Influenza vaccines may reduce mortality and CVD outcomes in these patients [<a href="#rid48">48-52</a>]. In a 2013 meta-analysis of trials conducted among persons with CVD or at high risk, those receiving an influenza vaccine had fewer cardiovascular events than those in the control group [<a href="#rid53">53</a>]. A randomized clinical trial of 2571 participants at 30 centers across eight countries found that primary outcomes (all-cause death, MI, and stent thrombosis) were less frequent in participants assigned influenza vaccine versus those assigned placebo (5.3 versus 7.2 percent) [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H45"><span class="h2">Therapies with uncertain or no benefit</span><span class="headingEndMark"> — </span>The following therapies have not been shown to improve outcomes in patients with CVD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antioxidant vitamins</strong> – Antioxidant vitamins, which are nonprescription and sold over the counter, have promising basic research and supportive observational data, but the randomized evidence has not demonstrated clinical benefits on CVD in secondary or primary prevention. The hypothesis that <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>, <a class="drug drug_general" data-topicid="9127" href="/d/drug information/9127.html" rel="external">beta-carotene</a>, and/or <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> decrease the risks of CVD has been tested in several large-scale randomized trials in secondary and primary prevention. The results have not supported either the potential beneficial mechanisms suggested from basic research or possible benefits hypothesized from observational studies [<a href="#rid55">55-58</a>]. (See  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homocysteine and </strong><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> – Although in observational studies, subjects with elevated levels of homocysteine have an increased risk of CHD, and given the fact that vitamin supplementation with folic acid lowers homocysteine levels, data from multiple randomized trials designed to test the hypothesis show no significant benefits of folic acid supplementation on the risks of CVD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postmenopausal hormone therapy</strong> – The relationship between postmenopausal hormone therapy and cardiovascular risk is discussed separately. (See  <a class="medical medical_review" href="/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chelation</strong> – The totality of evidence does not support a recommendation for chelation therapy in patients with CAD. There is only one randomized trial of this issue, the TACT trial. TACT assigned 1708 patients with prior MI at random to 40 infusions of a chelation solution or placebo over one to two years [<a href="#rid59">59</a>]. The primary composite endpoint (total mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for angina) occurred less frequently in the chelation group (26 versus 30 percent; HR 0.82, 95% CI 0.69-0.99) during a median follow-up of 4.6 years. This observed possible benefit needs to be interpreted in the context of the potential for unmasking and the use of multiple interim analyses, as well as the high rate of dropouts [<a href="#rid60">60</a>]. Further randomized evidence is necessary in order to make any evidence-based recommendations. Nonetheless, the 2014 American College of Cardiology/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society for Cardiovascular Angiography and Interventions/Society of Thoracic Surgeons focused update of prior guidelines for the diagnosis and management of patients with chronic coronary syndrome states that chelation therapy may be considered for reducing cardiovascular events [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholesteryl-ester transfer protein inhibitors</strong> – Inhibition of the cholesteryl-ester transfer protein (CETP) leads to large increases in high-density lipoprotein (HDL) and modest reductions in low-density lipoprotein (LDL). Of four large trials, three were terminated early, two for lack of benefit and one due to clear evidence of harm [<a href="#rid62">62</a>]. In the fourth trial, the addition of the CETP inhibitor anacetrapib to intensive statin treatment in patients with atherosclerotic vascular disease resulted in a modest but significantly lower incidence of major coronary events than the addition of placebo during four years of treatment. One intriguing subgroup finding in the trial of dalcetrapib suggested there may be ADCY9 genotype-dependent effects of this CETP inhibitor on biomarkers as well as clinical cardiovascular outcomes. These observations, at least in part, formed the basis for the ongoing dal-GenE randomized trial [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">The REVEAL trial compared anacetrapib with placebo in 30,449 patients with chronic atherosclerotic disease. After 4.1 years, anacetrapib-treated patients presented a lower incidence of the primary outcomes (major coronary event, a composite of coronary death, MI, or coronary revascularization) [10.8 versus 11.8 percent]). This benefit was considered statistically significant but not enough to continue research and development of the product [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> – Methotrexate has been postulated to lower the risk of CVD by reducing inflammation. However, in the Cardiovascular Inflammation Reduction Trial (CIRT) of 4786 patients with known MI or multivessel CAD who also had diabetes mellitus or metabolic syndrome, rates of the combined CVD outcome (nonfatal MI, nonfatal stroke, or cardiovascular death) were similar between the low-dose methotrexate (15 to 20 mg weekly) and placebo groups [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">Allopurinol</a><strong> –</strong> Among patients with gout, observational studies suggest that urate-lowering therapy with allopurinol is associated with lower CVD and mortality [<a href="#rid65">65,66</a>]. However, a larger trial of allopurinol in patients with ischemic heart disease and no history of gout did not show that it was efficacious in reducing rates of cardiovascular disease [<a href="#rid67">67</a>]. In the ALL-HEART open-label multicenter trial in the United Kingdom, 5937 participants aged ≥60 years were randomly assigned to receive allopurinol or usual care and followed for the composite outcome of MI, stroke, or cardiovascular death. After an average of 5 years, those assigned to allopurinol and those assigned to usual care had similar rates of the composite endpoint (11 versus 11.3 percent; HR 1.04, 95% CI 0.89-1.21). These results do not support the hypothesis that allopurinol be given to individuals with ischemic heart disease for secondary CVD prevention.</p><p></p><p class="headingAnchor" id="H924303633"><span class="h2">Revascularization</span><span class="headingEndMark"> — </span>The role of revascularization in patients with established CVD is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H315197"><span class="h1">PATIENT EDUCATION</span><span class="headingEndMark"> — </span>− Patient education regarding his or her risk factors and their management is central to secondary prevention. Patients with chronic coronary syndrome, also referred to as stable ischemic heart disease, should have an individualized education plan to optimize care and promote wellness that includes education on medication adherence; an explanation of medication management and cardiovascular risk reduction strategies in a manner that respects the patient’s level of understanding; a comprehensive review of all therapeutic options; a description of appropriate levels of exercise; introduction to self-monitoring skills; and information on how to recognize worsening cardiovascular symptoms and take appropriate action.</p><p class="headingAnchor" id="H3392053944"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109532.html" rel="external">"Society guideline links: Lipid disorders in adults"</a>.)</p><p class="headingAnchor" id="H48"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16238.html" rel="external">"Patient education: Medicines after an ischemic stroke (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16334.html" rel="external">"Patient education: Medicines after a heart attack (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2729.html" rel="external">"Patient education: Quitting smoking (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1989.html" rel="external">"Patient education: Exercise (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/3440.html" rel="external">"Patient education: High cholesterol and lipids (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/3428.html" rel="external">"Patient education: Aspirin in the primary prevention of cardiovascular disease and cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4424.html" rel="external">"Patient education: High blood pressure treatment in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1737.html" rel="external">"Patient education: Type 2 diabetes: Treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2725.html" rel="external">"Patient education: Risks and benefits of alcohol (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1990.html" rel="external">"Patient education: Diet and health (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1988.html" rel="external">"Patient education: Losing weight (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H49"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identifying patients at high risk</strong> – Patients with established coronary heart disease (CHD) have higher risks of subsequent cardiovascular events, including myocardial infarction (MI), stroke, and death from cardiovascular disease (CVD). (See <a class="local">'Identifying patients at high risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle modifications</strong> – Therapeutic lifestyle changes of proven benefit include avoidance or cessation of smoking, increasing levels of daily physical activity, and healthy diet. Modifications of multiple major risk factors may produce additive benefits. (See <a class="local">'Lifestyle modifications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Statins</strong> – We treat all patients with atherosclerotic CVD, as well as individuals with a 10-year risk &gt;20 percent, with evidence-based doses of a high-intensity statin regardless of the baseline LDL cholesterol. Specific recommendations are provided separately. (See  <a class="medical medical_review" href="/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> – Patients with established atherosclerotic CVD are treated with long-term aspirin therapy. Specific recommendations are provided separately. (see  <a class="medical medical_review" href="/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> – For patients with chronic coronary disease who are receiving other secondary preventive drug therapies, we suggest adding colchicine 0.5 (or 0.6) mg per day (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Colchicine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticoagulant therapy for some patients</strong> – For most patients with stable coronary artery disease (CAD) on antiplatelet therapy, we do not substitute or add a full-dose oral anticoagulant therapy to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. For some stable atherosclerotic CVD patients who are at high risk of cardiovascular events and at low risk for bleeding, a regimen of <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg orally twice per day and aspirin may be considered. (See <a class="local">'Anticoagulant therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other potential treatments</strong> – Other medications that may be of benefit in some patients include beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or aldosterone blockers. (See <a class="local">'Adjunctive therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021; 42:2439.</a></li><li><a class="nounderline abstract_t">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J 2016; 37:2315.</a></li><li><a class="nounderline abstract_t">Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011; 58:2432.</a></li><li class="breakAll">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).</li><li><a class="nounderline abstract_t">Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.</a></li><li class="breakAll">www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).</li><li><a class="nounderline abstract_t">Iestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation 2005; 112:924.</a></li><li><a class="nounderline abstract_t">Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121:750.</a></li><li><a class="nounderline abstract_t">Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292:1433.</a></li><li><a class="nounderline abstract_t">Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140:e596.</a></li><li><a class="nounderline abstract_t">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42:3227.</a></li><li><a class="nounderline abstract_t">Rimm EB, Appel LJ, Chiuve SE, et al. Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation 2018; 138:e35.</a></li><li><a class="nounderline abstract_t">Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083.</a></li><li><a class="nounderline abstract_t">Hennekens CH, Andreotti F. Leading avoidable cause of premature deaths worldwide: case for obesity. Am J Med 2013; 126:97.</a></li><li><a class="nounderline abstract_t">Krauss RM, Winston M, Fletcher RN, Grundy SM. Obesity: impact of cardiovascular disease. Circulation 1998; 98:1472.</a></li><li><a class="nounderline abstract_t">Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995; 273:461.</a></li><li><a class="nounderline abstract_t">Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333:677.</a></li><li><a class="nounderline abstract_t">Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305.</a></li><li><a class="nounderline abstract_t">van Dam RM, Rimm EB, Willett WC, et al. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med 2002; 136:201.</a></li><li><a class="nounderline abstract_t">Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481.</a></li><li class="breakAll">US Preventive Services Task Force. Final recommendation statement: Weight loss to prevent obesity-related morbidity and mortality in adults: Behavioral interventions. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/obesity-in-adults-interventions1 (Accessed on November 13, 2020).</li><li><a class="nounderline abstract_t">Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124:2458.</a></li><li><a class="nounderline abstract_t">Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290:86.</a></li><li><a class="nounderline abstract_t">Rea TD, Heckbert SR, Kaplan RC, et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137:494.</a></li><li><a class="nounderline abstract_t">Kritz H, Schmid P, Sinzinger H. Passive smoking and cardiovascular risk. Arch Intern Med 1995; 155:1942.</a></li><li><a class="nounderline abstract_t">Mayne SL, Widome R, Carroll AJ, et al. Longitudinal Associations of Smoke-Free Policies and Incident Cardiovascular Disease: CARDIA Study. Circulation 2018; 138:557.</a></li><li><a class="nounderline abstract_t">Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003; 348:109.</a></li><li><a class="nounderline abstract_t">Gémes K, Janszky I, Laugsand LE, et al. Alcohol consumption is associated with a lower incidence of acute myocardial infarction: results from a large prospective population-based study in Norway. J Intern Med 2016; 279:365.</a></li><li><a class="nounderline abstract_t">Arriola L, Martinez-Camblor P, Larrañaga N, et al. Alcohol intake and the risk of coronary heart disease in the Spanish EPIC cohort study. Heart 2010; 96:124.</a></li><li><a class="nounderline abstract_t">Roerecke M, Rehm J. Irregular heavy drinking occasions and risk of ischemic heart disease: a systematic review and meta-analysis. Am J Epidemiol 2010; 171:633.</a></li><li><a class="nounderline abstract_t">Ruidavets JB, Ducimetière P, Evans A, et al. Patterns of alcohol consumption and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). BMJ 2010; 341:c6077.</a></li><li><a class="nounderline abstract_t">Chow CK, Redfern J, Hillis GS, et al. Effect of Lifestyle-Focused Text Messaging on Risk Factor Modification in Patients With Coronary Heart Disease: A Randomized Clinical Trial. JAMA 2015; 314:1255.</a></li><li><a class="nounderline abstract_t">Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med 2019; 381:1309.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet 2019; 394:1169.</a></li><li><a class="nounderline abstract_t">Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA 2009; 302:2361.</a></li><li><a class="nounderline abstract_t">Hennekens CH, DeMets D. Statistical association and causation: contributions of different types of evidence. JAMA 2011; 305:1134.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377:1319.</a></li><li><a class="nounderline abstract_t">Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med 2022; 387:967.</a></li><li><a class="nounderline abstract_t">Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010; 105:21A.</a></li><li class="breakAll">https://secure.medicalletter.org/TML-article-1621d (Accessed on March 24, 2021).</li><li><a class="nounderline abstract_t">Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383:1838.</a></li><li><a class="nounderline abstract_t">Opstal TSJ, Fiolet ATL, van Broekhoven A, et al. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. J Am Coll Cardiol 2021; 78:859.</a></li><li><a class="nounderline abstract_t">Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J 2021; 42:2745.</a></li><li><a class="nounderline abstract_t">Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019; 381:2497.</a></li><li><a class="nounderline abstract_t">Tong DC, Quinn S, Nasis A, et al. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation 2020; 142:1890.</a></li><li><a class="nounderline abstract_t">Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. Circulation 2021; 143:528.</a></li><li><a class="nounderline abstract_t">Chow EJ, Rolfes MA, O'Halloran A, et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study. Ann Intern Med 2020; 173:605.</a></li><li><a class="nounderline abstract_t">Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 2004; 25:25.</a></li><li><a class="nounderline abstract_t">Phrommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011; 32:1730.</a></li><li><a class="nounderline abstract_t">Nguyen JL, Yang W, Ito K, et al. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol 2016; 1:274.</a></li><li><a class="nounderline abstract_t">Clar C, Oseni Z, Flowers N, et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015; :CD005050.</a></li><li><a class="nounderline abstract_t">Wu HH, Chang YY, Kuo SC, Chen YT. Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders-A propensity score-matched follow-up study. PLoS One 2019; 14:e0219172.</a></li><li><a class="nounderline abstract_t">Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013; 310:1711.</a></li><li><a class="nounderline abstract_t">Fröbert O, Götberg M, Erlinge D, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation 2021; 144:1476.</a></li><li><a class="nounderline abstract_t">Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Dagenais G, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342:154.</a></li><li><a class="nounderline abstract_t">Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447.</a></li><li><a class="nounderline abstract_t">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23.</a></li><li><a class="nounderline abstract_t">Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007; 167:1610.</a></li><li><a class="nounderline abstract_t">Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA 2013; 309:1241.</a></li><li><a class="nounderline abstract_t">Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). JAMA 2013; 309:1293.</a></li><li><a class="nounderline abstract_t">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64:1929.</a></li><li><a class="nounderline abstract_t">HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017; 377:1217.</a></li><li><a class="nounderline abstract_t">Tardif JC, Dubé MP, Pfeffer MA, et al. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. Am Heart J 2020; 222:157.</a></li><li><a class="nounderline abstract_t">Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med 2019; 380:752.</a></li><li><a class="nounderline abstract_t">Weisman A, Tomlinson GA, Lipscombe LL, et al. Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study. Diabetes Obes Metab 2019; 21:1322.</a></li><li><a class="nounderline abstract_t">Lai SW, Lin CL, Liao KF. Case-control study examining the association between allopurinol use and ischemic cerebrovascular disease. J Investig Med 2019; 67:48.</a></li><li><a class="nounderline abstract_t">Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022; 400:1195.</a></li></ol></div><div id="topicVersionRevision">Topic 1505 Version 96.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34120177" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27222591" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention&amp;Rehabilitation (EACPR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22055990" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22055990" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748199" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748199" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087812" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124123" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383513" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879355" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34458905" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773586" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299006" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331433" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Leading avoidable cause of premature deaths worldwide: case for obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841132" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Obesity: impact of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7654270" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637744" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Body weight and mortality among women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151467" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Obesity and the risk of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11827496" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dietary patterns and risk for type 2 diabetes mellitus in U.S. men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872581" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Weight gain as a risk factor for clinical diabetes mellitus in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872581" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Weight gain as a risk factor for clinical diabetes mellitus in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052934" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12837716" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230350" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Smoking status and risk for recurrent coronary events after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575047" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Passive smoking and cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735485" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Longitudinal Associations of Smoke-Free Policies and Incident Cardiovascular Disease: CARDIA Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519921" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26365927" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Alcohol consumption is associated with a lower incidence of acute myocardial infarction: results from a large prospective population-based study in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933099" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Alcohol intake and the risk of coronary heart disease in the Spanish EPIC cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142394" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Irregular heavy drinking occasions and risk of ischemic heart disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098615" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patterns of alcohol consumption and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393848" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of Lifestyle-Focused Text Messaging on Risk Factor Modification in Patients With Coronary Heart Disease: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31475798" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ticagrelor in Patients with Stable Coronary Disease and Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31484629" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952322" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406653" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Statistical association and causation: contributions of different types of evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844192" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36018037" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Polypill Strategy in Secondary Cardiovascular Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102970" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Are there effects of renin-angiotensin system antagonists beyond blood pressure control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102970" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Are there effects of renin-angiotensin system antagonists beyond blood pressure control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865380" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Colchicine in Patients with Chronic Coronary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34446156" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33961006" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Colchicine and the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31733140" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32862667" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33191772" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32833488" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14683739" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21289042" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27438105" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Seasonal Influenza Infections and Cardiovascular Disease Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940444" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Influenza vaccines for preventing cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31260487" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders-A propensity score-matched follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24150467" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34459211" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10639540" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vitamin E supplementation and cardiovascular events in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10465168" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114037" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698683" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532240" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532246" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Concerns about reliability in the Trial to Assess Chelation Therapy (TACT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25077860" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28847206" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32087417" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415610" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30734980" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30042112" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Case-control study examining the association between allopurinol use and ischemic cerebrovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36216006" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
